Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | One World Trade Center, Suite 8500 NEW YORK NY 10007 |
Tel: | N/A |
Website: | N/A |
IR: | N/A |
Key People | ||
Miriam Halperin Wernli Executive President | Robert Barrow Chief Executive Officer, Director | Schond Greenway Chief Financial Officer |
Carrie F. Liao Chief Accounting Officer | Daniel R. Karlin Chief Medical Officer | Francois Lilienthal Chief Commercial Officer | Mark R. Sullivan Chief Legal Officer, Corporate Secretary |
Business Overview |
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD). |
Financial Overview |
For the fiscal year ended 31 December 2023, Mind Medicine (MindMed) Inc revenues was not reported. Net loss increased 69% to $95.7M. Higher net loss reflects Fair Value Adjustments on Other Assets decrease from $7.8M (income) to $6.6M (expense), Research and development - Balancing val increase of 53% to $41.8M (expense), General and administrative - Balancing v increase of 51% to $33.3M (expense). |
Employees: | 57 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $584.08M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$90.67M as of Dec 31, 2023 |
Net annual income (TTM): | -$95.73M as of Dec 31, 2023 |
Free cash flow (TTM): | -$64.37M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 70,267,970 as of Mar 7, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |